One such application of EV-based gene therapy is the treatment of homozygous familial hypercholesterolemia (HFH), a severe genetic disorder where the low-density lipoprotein receptor (LDLR) gene is either deleted or showing a loss-of-function mutation. Here, LDLR is linked to homozygous familial hypercholesterolemia.